A randomized, double-blind, double-dummy, parallel-group study comparing the efficacy and safety of ofatumumab versus teriflunomide in patients with relapsing multiple sclerosis

drug protocol number
COMB157G2301
drug sponsor
Novartis
drug study
ofatumumab
drug trial site
KFSH&RC-J
drug status
Ongoing
drug phase